Literature DB >> 11468164

The impaired polymerization of fibrinogen Longmont (Bbeta166Arg-->Cys) is not improved by removal of disulfide-linked dimers from a mixture of dimers and cysteine-linked monomers.

K C Lounes1, J B Lefkowitz, A H Henschen-Edman, A I Coates, R R Hantgan, S T Lord.   

Abstract

This study identified a new substitution in the Bbeta chain of an abnormal fibrinogen, denoted Longmont, where the residue Arg166 was changed to Cys. The variant was discovered in a young woman with an episode of severe hemorrhage at childbirth and a subsequent mild bleeding disorder. The neo-Cys residues were always found to be disulfide-bridged to either an isolated Cys amino acid or to the corresponding Cys residue of another abnormal fibrinogen molecule, forming dimers. Removing the dimeric molecules using gel filtration did not correct the fibrin polymerization defect. Fibrinogen Longmont had normal fibrinopeptide A and B release and a functional polymerization site "a." Thus, the sites "A" and "a" can interact to form protofibrils, as evidenced by dynamic light-scattering measurements. These protofibrils, however, were unable to associate in the normal manner of lateral aggregation, leading to abnormal clot formation, as shown by an impaired increase in turbidity. Therefore, it is concluded that the substitution of Arg166-->Cys-Cys alters fibrinogen Longmont polymerization by disrupting interactions that are critical for normal lateral association of protofibrils. (Blood. 2001;98:661-666)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11468164     DOI: 10.1182/blood.v98.3.661

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Interstitial contacts in an RNA-dependent RNA polymerase lattice.

Authors:  Andres B Tellez; Jing Wang; Elizabeth J Tanner; Jeannie F Spagnolo; Karla Kirkegaard; Esther Bullitt
Journal:  J Mol Biol       Date:  2011-08-03       Impact factor: 5.469

2.  Identification of novel mutations in patients with fibrinogen disorders and genotype/phenotype correlations.

Authors:  Elena Chinni; Giovanni Tiscia; Giovanni Favuzzi; Filomena Cappucci; Giuseppe Malcangi; Rossana Bagna; Claudia Izzi; Domenica Rizzi; Valerio De Stefano; Elvira Grandone
Journal:  Blood Transfus       Date:  2018-10-08       Impact factor: 3.443

3.  Combined use of Clauss and prothrombin time-derived methods for determining fibrinogen concentrations: Screening for congenital dysfibrinogenemia.

Authors:  Liqun Xiang; Meiling Luo; Jie Yan; Lin Liao; Weijie Zhou; Xuelian Deng; Donghong Deng; Peng Cheng; Faquan Lin
Journal:  J Clin Lab Anal       Date:  2017-09-18       Impact factor: 2.352

4.  Missing regions within the molecular architecture of human fibrin clots structurally resolved by XL-MS and integrative structural modeling.

Authors:  Oleg Klykov; Carmen van der Zwaan; Albert J R Heck; Alexander B Meijer; Richard A Scheltema
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-10       Impact factor: 11.205

5.  Targeting Human Thrombus by Liposomes Modified with Anti-Fibrin Protein Binders.

Authors:  Hana Petroková; Josef Mašek; Milan Kuchař; Andrea Vítečková Wünschová; Jana Štikarová; Eliška Bartheldyová; Pavel Kulich; František Hubatka; Jan Kotouček; Pavlína Turánek Knotigová; Eva Vohlídalová; Renata Héžová; Eliška Mašková; Stuart Macaulay; Jan Evangelista Dyr; Milan Raška; Robert Mikulík; Petr Malý; Jaroslav Turánek
Journal:  Pharmaceutics       Date:  2019-12-02       Impact factor: 6.321

6.  Fibrinogen Longmont: A Clinically Heterogeneous Dysfibrinogenemia with Discrepant Fibrinogen Results Influenced by Clot Detection Method and Reagent.

Authors:  Becky Leung; Joanne Beggs; Jane Mason
Journal:  TH Open       Date:  2022-01-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.